Digital Monitoring of Self-reported Symptoms by Patients Treated With Cabozantinib Plus Nivolumab for Advanced Clear-cell Renal Carcinoma

The aim of the study is to evaluate the impact of digital monitoring of self-reported symptoms (PROs) on the adjustment of treatment management in patients treated with cabozantinib plus nivolumab for advanced clear cell renal cell carcinoma (RCC) in real life during the first 3 months of combined treatment

Trial Details

NCT ID
NCT07028125
Phase
PHASE4
Sponsor
Centre Francois Baclesse
Status
RECRUITING
Cancer Type
Kidney Cancer
Interventions
  • cabozantinib and nivolumab
Locations (sample)
  • Annecy, France|45.90878,6.12565
  • Avignon, France|43.94834,4.80892
  • Bayeux, France|49.27732,-0.7039
  • Boulogne-sur-Mer, France|50.72485,1.61373
  • Caen, France|49.18585,-0.35912

Key Eligibility Criteria

  • Patient older than 18 years
  • Diagnosis of advanced/metastatic Renal Cell Carcinoma (RCC) with a clear-cell component
  • No prior systemic treatment for RCC
  • Physician-initiated decision prior to study enrollment to treat with cabozantinib and nivolumab in combination, in first line for advanced/metastat…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Kidney Cancer Trials on Trialify →